Johnson & Johnson (JNJ) Gains from Investment Securities (2020)
Johnson & Johnson's (JNJ) quarterly Gains from Investment Securities came in at -$200.0 million in Q3 2020, up 80.0% quarter-over-quarter from -$1.0 billion in Q2 2020.
Powered by 
Analysis
Johnson & Johnson (JNJ) Gains from Investment Securities (2020) Analysis & Trends
Johnson & Johnson has disclosed Gains from Investment Securities across 1 years of filings, most recently posting -$200.0 million for Q3 2020.
- In Q3 2020, Gains from Investment Securities changed N/A year-over-year to -$200.0 million; the TTM figure through Jul 2021 stood at -$200.0 million (up 89.91% YoY), while the FY2021 annual figure was -$1.1 billion, changed N/A from the prior year.
- Gains from Investment Securities came in at -$200.0 million for Q3 2020 at Johnson & Johnson, up from -$1.0 billion in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of -$200.0 million in Q3 2020 to a low of -$1.0 billion in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 27, 2020 | -200.00 Mn |
| Jun 28, 2020 | -1.00 Bn |
| Mar 29, 2020 | -983.00 Mn |